Literature DB >> 8943434

Immune reactivity of diabetes-associated human monoclonal autoantibodies defines multiple epitopes and detects two domain boundaries in glutamate decarboxylase.

K Syren1, L Lindsay, B Stoehrer, K Jury, F Lühder, S Baekkeskov, W Richter.   

Abstract

Autoreactive islet cell Abs (ICA) accompany the pathogenic destruction of pancreatic beta cells in insulin-dependent diabetes mellitus (IDDM). Human monoclonal ICA (MICA 1-6), previously derived from a DR1/DR7-positive newly diagnosed diabetic patient, recognized the islet cell autoantigen glutamate decarboxylase 65 (GAD65) and defined two distinct conformational (MICA 1/3 and MICA 4/6) and one linear (MICA 2) autoimmune epitopes in this molecule. We have isolated 4 new ICA-reactive B cell lines, one from a DR4/DR11-positive newly diagnosed IDDM patient (MICA 7) and three from a DR3 homozygous patient with both IDDM and Graves' disease (MICA 8-10). Like MICA 1-6, MICA 7-10 are specific for GAD65, suggesting that GAD65-reactive B cells dominate the ICA response in IDDM. Comparative analysis of MICA 1-6 and MICA 7-10, using GAD65 mutants and blocking experiments, showed that MICA 7-10 define three novel conformational autoimmune epitopes in GAD65. Further structural analysis of the MICA 1-10 epitopes revealed two distinct and one overlapping region of epitope clusters. Thus, the C-terminal region, defined by amino acids 450 to 570, harbors the conformational MICA1/3 and MICA 7 epitopes as well as the linear epitope of MICA 2 (amino acids 506-531). The MICA 4/6 and MICA 10 epitopes are located in the middle region of the molecule defined by amino acids 245 to 449, whereas the N-terminal region contributes only to the MICA 8/9 epitopes (encompassed in amino acids 39-585). MICA 1-6, 7, and 8-10, derived from three IDDM patients of different HLA haplotypes, define six different epitopes in GAD65 and represent tools to determine the spectrum, possible HLA association, and temporal order of epitope recognition in IDDM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943434

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Molecular mapping of epitopes on melanocyte-specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo.

Authors:  E H Kemp; E A Waterman; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Authors:  A C Powers; K Bavik; J Tremble; K Daw; W A Scherbaum; J P Banga
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

3.  Reduced display of conformational epitopes in the N-terminal truncated GAD65 isoform: relevance for people with stiff person syndrome or DQ8/8-positive Type 1 diabetes mellitus.

Authors:  C S Hampe; J R Radtke; A Wester; A Carlsson; E Cedervall; B Jönsson; S A Ivarsson; H Elding Larsson; K Larsson; B Lindberg; J Neiderud; O Rolandsson; Å Lernmark
Journal:  Diabet Med       Date:  2018-12-28       Impact factor: 4.359

4.  Identification of antigenic domains on the human sodium-iodide symporter which are recognized by autoantibodies from patients with autoimmune thyroid disease.

Authors:  E H Kemp; E A Waterman; R A Ajjan; K A Smith; P F Watson; M E Ludgate; A P Weetman
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

5.  Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis.

Authors:  T A M A Al-Bukhari; P M Radford; G Bouras; C Davenport; S M Trigwell; G-F Bottazzo; M Lai; H L Schwartz; P J Tighe; I Todd
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

6.  Autoantibodies from patients with coeliac disease recognize distinct functional domains of the autoantigen tissue transglutaminase.

Authors:  J Seissler; U Wohlrab; C Wuensche; W A Scherbaum; B O Boehm
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

7.  Multiplicity of the antibody response to GAD65 in Type I diabetes.

Authors:  L K Gilliam; K A Binder; J P Banga; A-M Madec; E Ortqvist; I Kockum; D Luo; C S Hampe
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

8.  Modulation of antigen presentation by autoreactive B cell clones specific for GAD65 from a type I diabetic patient.

Authors:  J P Banga; J K Moore; N Duhindan; A M Madec; P M van Endert; J Orgiazzi; J Endl
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

9.  Conformation-dependent GAD65 autoantibodies in diabetes.

Authors:  D Luo; L K Gilliam; C Greenbaum; L Bekris; C S Hampe; T Daniels; W Richter; S M Marcovina; O Rolandsson; M Landin-Olsson; I Kockum; A Lernmark
Journal:  Diabetologia       Date:  2004-09-08       Impact factor: 10.122

10.  Mapping of human autoantibody binding sites on the calcium-sensing receptor.

Authors:  E Helen Kemp; Nikos G Gavalas; Samia Akhtar; Kai J E Krohn; J Carl Pallais; Edward M Brown; Philip F Watson; Anthony P Weetman
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.